CEO Tehila Ben-Moshe (Biond Biologics)
January 12, 2021 08:15 AM ESTUpdated 09:41 AM
Deals

Dou­bling down on on­col­o­gy, Sanofi buys in­to a new check­point in­hibitor with a $125M down pay­ment

Nicole DeFeudis

Editor

On its lat­est shop­ping trip through the im­muno-on­col­o­gy de­part­ment, Sanofi picked up the rights to a check­point in­hibitor from Biond Bi­o­log­ics’ pipeline, pay­ing over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times